PDS Biotechnology Corp
PDSB1.095USD
+0.005+0.46%
取引時間 （ET）15分遅れの株価
49.76M時価総額
損失額直近12ヶ月PER
詳細情報 PDS Biotechnology Corp 企業名
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
企業情報
企業コードPDSB
会社名PDS Biotechnology Corp
上場日Oct 01, 2015
最高経営責任者「CEO」Dr. Frank Bedu-Addo, Ph.D.
従業員数24
証券種類Ordinary Share
決算期末Oct 01
本社所在地303A College Road East
都市PRINCETON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号08540
電話番号18002083343
ウェブサイトhttps://www.pdsbiotech.com
企業コードPDSB
上場日Oct 01, 2015
最高経営責任者「CEO」Dr. Frank Bedu-Addo, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Jul 26
更新時刻: Sat, Jul 26
株主統計
種類
株主統計
株主統計
比率
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
株主統計
株主統計
比率
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
種類
株主統計
比率
Hedge Fund
9.80%
Investment Advisor
6.01%
Individual Investor
3.09%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.71%
Pension Fund
0.04%
Bank and Trust
0.01%
Other
78.80%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
187
9.67M
21.15%
+1.28M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
2023Q1
149
11.76M
39.00%
-275.25K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Armistice Capital LLC
4.42M
9.67%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
3.3%
+4.41K
+0.29%
Mar 31, 2025
Bedu-Addo (Frank)
690.87K
1.51%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
480.97K
1.05%
-4.48K
-0.92%
Mar 31, 2025
Sykes (Richard)
445.11K
0.97%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
437.88K
0.96%
+20.66K
+4.95%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
257.20K
0.56%
+99.70K
+63.30%
Mar 31, 2025
UBS Financial Services, Inc.
245.33K
0.54%
+221.67K
+936.97%
Mar 31, 2025
State Street Global Advisors (US)
133.33K
0.29%
--
--
Mar 31, 2025
Conn (Gregory L Ph.D.)
123.59K
0.27%
--
--
Apr 17, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
詳細を見る
iShares Micro-Cap ETF
比率0.01%
DFA Dimensional US Core Equity Market ETF
比率0%
Global X Russell 2000 ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
iShares Russell 2000 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
Global X Russell 2000 Covered Call ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
